Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells

Genome Biology

Volumn 14, Issue 1, 2013, Pages

  Sanders, Deborah A ^a   Ross Innes, Caryn S ^a   Beraldi, Dario ^a   Carroll, Jason S ^a,b   Balasubramanian, Shankar ^a,b,c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; ESTROGEN RECEPTOR ALPHA; PROTEIN CARM1; THIOSTREPTON; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; COACTIVATOR-ASSOCIATED ARGININE METHYLTRANSFERASE 1; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN BINDING; TRANSCRIPTOME;

ARTICLE; BINDING SITE; BREAST CANCER CELL LINE; CELL CYCLE REGULATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENE LOCATION; GENE MAPPING; GENOME ANALYSIS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; INHIBITION KINETICS; MCF 7 CELL LINE; PROGNOSIS; PROMOTER REGION; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN GENOME; METABOLISM;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MCF-7 CELLS; PROTEIN BINDING; PROTEIN-ARGININE N-METHYLTRANSFERASES; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84872686976     PISSN: 14747596     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/gb-2013-14-1-r6     Document Type: Article

References (84)

1. Korver W, Roose J, Clevers H: The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic Acids Res 1997, 25:1715-1719.
2. Costa RH: FoxM1 dances with mitosis. Nat Cell Biol 2005, 7:108-110.
3. Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, Tan Y, Ackerson T, Costa RH: Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 2005, 25:10875-10894.
4. Wonsey DR, Follettie MT: Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005, 65:5181-5189.
5. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007, 67:8293-8300.
6. Raychaudhuri P, Park HJ: FoxM1: a master regulator of tumor metastasis. Cancer Res 2011, 71:4329-4333.
7. Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, Tyner AL, Lau LF, Costa RH, Raychaudhuri P: FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J 2009, 28:2908-2918.
8. Alvarez-Fernandez M, Halim VA, Krenning L, Aprelia M, Mohammed S, Heck AJ, Medema RH: Recovery from a DNA-damage-induced G2 arrest requires Cdk-dependent activation of FoxM1. EMBO Rep 2010, 11:452-458.
9. Pilarsky C, Wenzig M, Specht T, Saeger HD, Grutzmann R: Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 2004, 6:744-750.
10. Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB: FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem 2012, 114:755-762.
11. Priller M, Poschl J, Abrao L, von Bueren AO, Cho YJ, Rutkowski S, Kretzschmar HA, Schuller U: Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res 2011, 17:6791-6801.
12. Teh MT, Gemenetzidis E, Chaplin T, Young BD, Philpott MP: Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol Cancer 2010, 9:45.
13. Gemenetzidis E, Elena-Costea D, Parkinson EK, Waseem A, Wan H, Teh MT: Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res 2010, 70:9515-9526.
14. Park YY, Jung SY, Jennings N, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood A, Lee JS: FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 2012, 33:1843-1853.
15. Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, Palmieri C, Peston D, Shousha S, Yu Q, Sicinski P, Coombes RC, Lam EW: FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol 2009, 35:57-68.
16. Bektas N, Haaf A, Veeck J, Wild PJ, Luscher-Firzlaff J, Hartmann A, Knuchel R, Dahl E: Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 2008, 8:42.
17. Bergamaschi A, Christensen BL, Katzenellenbogen BS: Reversal of endocrine resistance in breast cancer: interrelationships among 14-3- 3zeta, FOXM1, and a gene signature associated with mitosis. Breast Cancer Res 2011, 13:R70.
18. Abba MC, Lacunza E, Butti M, Aldaz CM: Breast cancer biomarker discovery in the functional genomic age: a systematic review of 42 gene expression signatures. Biomarker Insights 2010, 5:103-118.
19. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, Myatt SS, Lam EW: FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 2010, 8:24-34.
20. Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P: FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 2010, 70:5054-5063.
21. Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema RH, Hartman J, Lykkesfeldt AE, Lam EW: FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 2010, 29:2983-2995.
22. Madureira PA, Varshochi R, Constantinidou D, Francis RE, Coombes RC, Yao KM, Lam EW: The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem 2006, 281:25167-25176.
23. Weisz A, Basile W, Scafoglio C, Altucci L, Bresciani F, Facchiano A, Sismondi P, Cicatiello L, De Bortoli M: Molecular identification of ERalphapositive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. J Cell Physiol 2004, 200:440-450.
24. Yau C, Wang Y, Zhang Y, Foekens JA, Benz CC: Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers. Breast Cancer Res Treat 2011, 126:803-810.
25. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS: FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 2011, 43:27-33.
26. Tang Q, Chen Y, Meyer C, Geistlinger T, Lupien M, Wang Q, Liu T, Zhang Y, Brown M, Liu XS: A comprehensive view of nuclear receptor cancer cistromes. Cancer Res 2011, 71:6940-6947.
27. McLeay RC, Bailey TL: Motif Enrichment Analysis: a unified framework and an evaluation on ChIP data. BMC Bioinformatics 2010, 11:165.
28. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS: Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481:389-393.
29. Joseph R, Orlov YL, Huss M, Sun W, Kong SL, Ukil L, Pan YF, Li G, Lim M, Thomsen JS, Ruan Y, Clarke ND, Prabhakar S, Cheung E, Liu ET: Integrative model of genomic factors for determining binding site selection by estrogen receptor-alpha. Mol Systems Biol 2010, 6:456.
30. Sadasivam S, Duan S, DeCaprio JA: The MuvB complex sequentially recruits B-Myb and FoxM1 to promote mitotic gene expression. Genes Dev 2012, 26:474-489.
31. Chen X, Muller GA, Quaas M, Fischer M, Han N, Stutchbury B, Sharrocks AD, Engeland K: The forkhead transcription factor FOXM1 controls cell cycledependent gene expression through an atypical chromatin binding mechanism. Mol Cell Biol 2012, 33:227-236.
32. Ross-Innes CS, Brown GD, Carroll JS: A co-ordinated interaction between CTCF and ER in breast cancer cells. BMC Genomics 2011, 12:593.
33. Klinge CM, Jernigan SC, Mattingly KA, Risinger KE, Zhang J: Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors. J Mol Endocrinol 2004, 33:387-410.
34. Osborne CK, Wakeling A, Nicholson RI: Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 2004, 90(Suppl 1):S2-6.
35. Bhat UG, Halasi M, Gartel AL: FoxM1 is a general target for proteasome inhibitors. PloS One 2009, 4:e6593.
36. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F: Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003, 115:751-763.
37. Al-Dhaheri M, Wu J, Skliris GP, Li J, Higashimato K, Wang Y, White KP, Lambert P, Zhu Y, Murphy L, Xu W: CARM1 is an important determinant of ERalpha-dependent breast cancer cell differentiation and proliferation in breast cancer cells. Cancer Res 2011, 71:2118-2128.
38. Naeem H, Cheng D, Zhao Q, Underhill C, Tini M, Bedford MT, Torchia J: The activity and stability of the transcriptional coactivator p/CIP/SRC-3 are regulated by CARM1-dependent methylation. Mol Cell Biol 2007, 27:120-134.
39. Ceschin DG, Walia M, Wenk SS, Duboe C, Gaudon C, Xiao Y, Fauquier L, Sankar M, Vandel L, Gronemeyer H: Methylation specifies distinct estrogen-induced binding site repertoires of CBP to chromatin. Genes Dev 2011, 25:1132-1146.
40. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, Gartel AL: Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res 2006, 66:9731-9735.
41. Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D, Lam EW: Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther 2008, 7:2022-2032.
42. Hegde NS, Sanders DA, Rodriguez R, Balasubramanian S: The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem 2011, 3:725-731.
43. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W, Liu XS: Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008, 9:R137.
44. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, Bejerano G: GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 2010, 28:495-501.
45. Bhat UG, Halasi M, Gartel AL: Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PloS One 2009, 4:e5592.
46. Tomlinson DC, Baxter EW, Loadman PM, Hull MA, Knowles MA: FGFR1- induced epithelial to mesenchymal transition through MAPK/ PLCgamma/COX-2-mediated mechanisms. PloS One 2012, 7:e38972.
47. Koziczak M, Holbro T, Hynes NE: Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004, 23:3501-3508.
48. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550.
49. Gozgit JM, Pentecost BT, Marconi SA, Ricketts-Loriaux RS, Otis CN, Arcaro KF: PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. Br J Cancer 2007, 97:809-817.
50. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS: Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004, 64:1522-1533.
51. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006, 25:3994-4008.
52. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008, 68:3108-3114.
53. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008, 68:826-833.
54. Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, Ethier SP, Clarke R: ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res 2008, 68:8908-8917.
55. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R: Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 2008, 68:7493-7501.
56. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
57. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25:1239-1246.
58. Snel B, Lehmann G, Bork P, Huynen MA: STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res 2000, 28:3442-3444.
59. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG: FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res 2002, 62:4773-4780.
60. Kalinichenko VV, Major ML, Wang X, Petrovic V, Kuechle J, Yoder HM, Dennewitz MB, Shin B, Datta A, Raychaudhuri P, Costa RH: Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev 2004, 18:830-850.
61. Teh MT, Gemenetzidis E, Patel D, Tariq R, Nadir A, Bahta AW, Waseem A, Hutchison IL: FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma. PloS One 2012, 7:e34329.
62. Huang C, Qiu Z, Wang L, Peng Z, Jia Z, Logsdon CD, Le X, Wei D, Huang S, Xie K: A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res 2012, 72:655-665.
63. Bauer UM, Daujat S, Nielsen SJ, Nightingale K, Kouzarides T: Methylation at arginine 17 of histone H3 is linked to gene activation. EMBO Rep 2002, 3:39-44.
64. Frietze S, Lupien M, Silver PA, Brown M: CARM1 regulates estrogenstimulated breast cancer growth through up-regulation of E2F1. Cancer Res 2008, 68:301-306.
65. Major ML, Lepe R, Costa RH: Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylationdependent recruitment of p300/CBP coactivators. Mol Cell Biol 2004, 24:2649-2661.
66. Wierstra I, Alves J: Transcription factor FOXM1c is repressed by RB and activated by cyclin D1/Cdk4. Biol Chem 2006, 387:949-962.
67. Wierstra I, Alves J: FOXM1c is activated by cyclin E/Cdk2, cyclin A/Cdk2, and cyclin A/Cdk1, but repressed by GSK-3alpha. Biochem Biophys Res Commun 2006, 348:99-108.
68. Anders L, Ke N, Hydbring P, Choi YJ, Widlund HR, Chick JM, Zhai H, Vidal M, Gygi SP, Braun P, Sicinski P: A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011, 20:620-634.
69. Alvarez-Fernandez M, Halim VA, Aprelia M, Laoukili J, Mohammed S, Medema RH: Protein phosphatase 2A (B55alpha) prevents premature activation of forkhead transcription factor FoxM1 by antagonizing cyclin A/cyclin-dependent kinase-mediated phosphorylation. J Biol Chem 2011, 286:33029-33036.
70. Petrovic V, Costa RH, Lau LF, Raychaudhuri P, Tyner AL: Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin. Cancer Biol Ther 2010, 9:1008-1016.
71. Carr JR, Kiefer MM, Park HJ, Li J, Wang Z, Fontasarosa J, DeWaal D, Kopanja D, Benevolenskaya EV, Guzman G, Raychaudhuri P: FOXM1 regulates mammary luminal cell fate. Cell Reports 2012, 1-15.
72. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko A, Sankila A, Turunen JP, Lundin M, Konsti J, Vesterinen T, Nordling S, Kallioniemi O, Hautaniemi S, Janne OA: Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 2011, 30:3962-3976.
73. Gene Expression Omnibus. [http://www.ncbi.nlm.nih.gov/geo/].
74. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT: ChIPseq: using high-throughput sequencing to discover protein-DNA interactions. Methods 2009, 48:240-248.
75. Robinson MD, McCarthy DJ, Smyth GK: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26:139-140.
76. McCarthy DJ, Chen Y, Smyth GK: Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res 2012, 40:4288-4297.
77. Saldanha AJ: Java Treeview-extensible visualization of microarray data. Bioinformatics 2004, 20:3246-3248.
78. Shin H, Liu T, Manrai AK, Liu XS: CEAS: cis-regulatory element annotation system. Bioinformatics 2009, 25:2605-2606.
79. Cistrome. [http://cistrome.org/ap/].
80. wordcloud. [http://CRAN.R-project.org/package=wordcloud].
81. Supek F, Bosnjak M, Skunca N, Smuc T: REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One 2011, 6:e21800.
82. Bararia D, Trivedi AK, Zada AA, Greif PA, Mulaw MA, Christopeit M, Hiddemann W, Bohlander SK, Behre G: Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha. Leukemia 2008, 22:800-807.
83. Gene Set Enrichment Analysis. [http://www.broadinstitute.org/gsea/].
84. The R Project for Statistical Computing. [http://www.R-project.org].